NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have received a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $8.50.

Several brokerages have recently issued reports on NRSN. D. Boral Capital restated a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Wednesday, April 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Friday, May 8th.

Insider Buying and Selling

In other NeuroSense Therapeutics news, CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief financial officer owned 1,504,050 shares in the company, valued at approximately $1,203,240. The trade was a 19.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Alon Ben-Noon acquired 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief executive officer owned 4,534,233 shares in the company, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 27.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NRSN. Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics in the third quarter valued at $26,000. Jane Street Group LLC acquired a new stake in NeuroSense Therapeutics during the 2nd quarter worth about $54,000. Squarepoint Ops LLC raised its stake in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares during the last quarter. Finally, Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics during the 4th quarter valued at about $77,000. 1.04% of the stock is currently owned by institutional investors and hedge funds.

NeuroSense Therapeutics Stock Performance

Shares of NRSN opened at $0.73 on Monday. The stock has a 50-day moving average of $0.78 and a two-hundred day moving average of $0.83. The stock has a market cap of $23.72 million, a P/E ratio of -1.35 and a beta of 1.58. NeuroSense Therapeutics has a one year low of $0.63 and a one year high of $2.14.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.